Education
About Us
Working with TipRanks
Follow Us
Microbix Biosystms J (TSE:MBX)
TSX:MBX
MBX Stock Chart & Stats
C$0.24
-C$0.01(-2.33%)
At close: 4:00 PM EST
C$0.24
-C$0.01(-2.33%)
Day’s Range― - ―
52-Week RangeC$0.21 - C$0.45
Previous CloseN/A
Volume37.35K
Average Volume (3M)57.61K
Market Cap
C$33.25M
Enterprise ValueC$33.71M
Total Cash (Recent Filing)C$9.10M
Total Debt (Recent Filing)C$8.11M
Price to Earnings (P/E)―
Beta-0.15
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding138,553,380
10 Day Avg. Volume59,614
30 Day Avg. Volume57,610
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.33
Price to Sales (P/S)1.98
P/FCF Ratio-42.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.50Price Target Upside108.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business DiversificationDiversification of antigen sales into additional channels reduces dependence on a few markets and lowers client concentration risk.
Earnings BeatQuarterly results surpassed analyst estimates, reflecting stronger-than-expected company performance that can support investor confidence.
Royalty Revenue ContributionRoyalty income bolstered reported revenues, creating a recurring revenue element that can stabilize cash flow beyond product sales.
Bears Say
China Demand WeaknessReduced shipments into China weakened antigen revenue and may pressure top-line while customers work through existing inventories.
Customer Concentration RiskRevenue decline was driven by issues at two large clients, highlighting customer concentration that poses downside risk to future sales.
Seasonal Demand VariabilityA milder respiratory virus season sharply reduced antigen demand, producing material year-over-year revenue declines and increasing uncertainty about recovery timing.
Microbix Biosystms News
MBX FAQ
What was Microbix Biosystms J’s price range in the past 12 months?
Microbix Biosystms J lowest stock price was C$0.21 and its highest was C$0.45 in the past 12 months.
What is Microbix Biosystms J’s market cap?
Microbix Biosystms J’s market cap is C$33.25M.
When is Microbix Biosystms J’s upcoming earnings report date?
Microbix Biosystms J’s upcoming earnings report date is May 14, 2026 which is in 58 days.
How were Microbix Biosystms J’s earnings last quarter?
Microbix Biosystms J released its earnings results on Feb 12, 2026. The company reported -C$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.008.
Is Microbix Biosystms J overvalued?
According to Wall Street analysts Microbix Biosystms J’s price is currently Undervalued.
Does Microbix Biosystms J pay dividends?
Microbix Biosystms J does not currently pay dividends.
What is Microbix Biosystms J’s EPS estimate?
Microbix Biosystms J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microbix Biosystms J have?
Microbix Biosystms J has 138,553,380 shares outstanding.
What happened to Microbix Biosystms J’s price movement after its last earnings report?
Microbix Biosystms J reported an EPS of -C$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.174%.
Which hedge fund is a major shareholder of Microbix Biosystms J?
Currently, no hedge funds are holding shares in TSE:MBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Microbix Biosystms J
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
MBX Stock 12 Month Forecast
Average Price Target
C$0.50
▲(108.33% Upside)
Technical Analysis
BriaCell Therapeutics
―
Resverlogix
―
Devonian Health Group
―
Defence Therapeutics
―
Thiogenesis Therapeutics Corp
―
Options Prices
Currently, No data available
---